Table 2.
NT-proBNP, inflammatory markers, osteoprotegerin and fetuin-A during treatment with vitamin D analogs
| |
Period 1 |
Period 2 |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |
Alfacalcidol |
Paricalcitol |
Difference between groups |
Alfacalcidol |
Paricalcitol |
Difference between groups | ||||||||
| Week 6 | Week 22 | Increase | Week 6 | Week 22 | Increase | Week 28 | Week 44 | Increase | Week 28 | Week 44 | Increase | |||
| NT-proBNP (pmol/l) median (range) |
417.8 (78-19048) N = 26 |
606.2 (90-63974) |
187.7 (-888-44932) |
485.4 (79-13543) N = 29 |
785.5 (39-7766) |
300.1 (-12433-6124)* |
-121.1 (95%CI -429.4 to 187.2) |
763.8 (55-2769) N = 29 |
1005.0 (43-8519) |
155.8 (-1917-7680) |
497.1 (54-42379) N = 26 |
487.6 (45-53669) |
-42.1 (-3262-11290) |
-429.7 (95%CI -938.1 to 78.8) |
| Log NT-proBNP |
2.74 (0.60) N = 26 |
6.63 (1.47) |
3.89 (0.19)# |
2.76 (0.57) N = 29 |
6.69 (1.22) |
3.93 (0.17)# |
0.04 (95%CI -0.54 to 0.47) |
6.39 (1.07) N = 29 |
6.73 (1.21) |
0.34 (0.19) |
6.60 (1.53) N = 26 |
6.37 (1.49) |
-0.22 (0.13) |
-0.56 (95% CI -1.04 to -0.10)¤ |
| hs-Crp (mg/l) median (range) |
9.61 (0.3 -28.0) N = 24 |
6.58 (0.4-73.2) |
-0.07 (-21-63) |
7.23 (0.3-27.7) N = 29 |
5.30 (0.3-81.0) |
-0.01 (-21-66) |
-0.76 (95%CI -5.9 to 4.4) |
7.52 (0.6-62.4) N = 29 |
5.25 (0.2-34.3) |
-0.31 (-55-11) |
6.96 (0.25-48.3) N = 24 |
5.46 (0.37-60.8) |
-1.18 (-46- 58) |
-0.85 (95%CI -4.7 to 3.0) |
| Log hs-Crp |
1.86 (1.20) N = 24 |
1.80 (1.38) |
-0.06 (0.21) |
1.54 (1.31) N = 29 |
1.58 (1.54) |
0.03 (0.21) |
0.09 (95%CI -0.69 to 0.51) |
1.70 (1.29) N = 29 |
1.38 (1.38) |
-0.32 (0.19) |
1.93 (1.26) N = 24 |
1.67 (1.08) |
-0.27 (0.27) |
0.05 (95%CI -0.60 to 0.71) |
| IL-6 (pg/ml) |
6.99 (5.34) N = 21 |
7.05 (8.40) |
0.06 (1.90) |
5.56 (3.68) N = 24 |
8.34 (14.24) |
2.79 (2.64) |
-2.73 (95%CI -9.47 to 4.01) |
6.59 (3.51) N = 21 |
5.66 (5.21) |
-0.93 (0.75) |
6.11 (3.91) N = 24 |
5.90 (3.53) |
-0.21 (1.07) |
0.72 (95%CI -1.87 to 3.29) |
| TNF-α (pg/ml) |
6.63 (2.45) N = 23 |
7.76 (6.16) |
1.13 (1.32) |
7.05 (2.20) N = 26 |
6.85 (2.28) |
-0.21 (0.44) |
1.34 (95%CI -1.33 to 4.00) |
6.59 (2.36) N = 26 |
7.18 (3.00) |
0.53 (1.32) |
6.42 (2.26) N = 23 |
7.04 (2.19) |
-1.22 (2.16) |
- 1.75 (95%CI -6.72 to 3.21) |
| Fetuin-A (μg/ml) |
319.15 (76.41) N = 23 |
362.92 (77.77) |
43.77 (14.07)# |
330.81 (81.83) N = 26 |
340.75 (84.98) |
9.93 (9.62) |
32.84 (95%CI 0.21 to 67.47) ¤ |
331.29 (107.15) N = 26 |
318.94 (91.32) |
-12.35 (18.39) |
329.55 (81.00) N = 23 |
299.20 (74.95) |
-30.35 (22.26) |
-42.7 (95%CI -75.62 to 33.69) |
| Osteoprotegerin (pg/ml) | 4461.77 (1905.1), N = 22 | 4878.00 (1954.20) | 416.23 (178.52)# | 4009.39 (1636.80) N = 26 | 4442.15 (2147.7) | 432.77 (193.65)# | 16.54 (95%CI -544.13 to 521.05) | 4333.4 (1947.1) N = 26 | 4567.04 (2003.1) | 233.64 (102.55)# | 4982.68 (1988.9) N = 22 | 4911.09 (1874.4) | -71.59 (209.52) | 305.23 (95%CI -757.83 to 147.36) |
Distribution of NT-proBNP and hs-Crp was skewed and analyses were done by Mann-Whitney two sample test and presented with Hodge-Lehman median (95% confidence interval).
Logarithmic transformed NT-proBNP and hs-Crp and the remaining parameters were compared using an unpaired t-test and presented with the mean difference (95% confidence intervals).
*: Wilcoxon signed rank test P<0.05; #: Two-sample paired t-test P < 0.05; ¤: Two-sample unpaired t-test, P < 0.05. Parameters are presented as mean (SD) and differences in mean (SEM) unless specified otherwise.